CenterBook Partners LP acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 9,546 shares of the company's stock, valued at approximately $702,000.
Several other hedge funds also recently bought and sold shares of the company. Capital International Investors grew its stake in AstraZeneca by 1.9% during the fourth quarter. Capital International Investors now owns 37,507,159 shares of the company's stock valued at $2,457,706,000 after acquiring an additional 686,008 shares in the last quarter. Bank of America Corp DE grew its stake in AstraZeneca by 189.3% in the 4th quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock worth $1,574,247,000 after buying an additional 15,722,197 shares in the last quarter. Franklin Resources Inc. grew its stake in AstraZeneca by 1.9% in the 4th quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock worth $1,276,367,000 after buying an additional 357,894 shares in the last quarter. Sanders Capital LLC grew its stake in AstraZeneca by 1.4% in the 4th quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock worth $995,032,000 after buying an additional 212,301 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in AstraZeneca by 30.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company's stock worth $1,003,124,000 after buying an additional 3,224,251 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the stock. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. BNP Paribas began coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of "Moderate Buy" and an average price target of $89.00.
View Our Latest Research Report on AstraZeneca
AstraZeneca Trading Down 0.7%
NASDAQ:AZN traded down $0.47 during midday trading on Friday, reaching $68.79. 2,991,789 shares of the stock traded hands, compared to its average volume of 5,276,511. The company has a fifty day moving average of $70.78 and a 200 day moving average of $70.92. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. The stock has a market capitalization of $213.34 billion, a P/E ratio of 27.63, a PEG ratio of 1.27 and a beta of 0.37.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The company's revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.06 EPS. On average, research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
